platinum has been researched along with jatrorrhizine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, XL; Liang, H; Qin, QP; Tan, MX; Wang, SL; Wang, ZF; Zhang, Y; Zou, BQ | 1 |
| Hu, J; Liu, W; Lu, K; Lu, Z; Ma, B; Wang, Y; Wei, W; Wen, D | 1 |
2 other study(ies) available for platinum and jatrorrhizine
| Article | Year |
|---|---|
High in vitro and in vivo antitumor activities of luminecent platinum(II) complexes with jatrorrhizine derivatives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Berberine; Cell Survival; DNA Damage; Fluorescent Dyes; HeLa Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Optical Imaging; Organoplatinum Compounds; Platinum; Telomerase | 2019 |
Apoptosis Activation in Thyroid Cancer Cells by Jatrorrhizine-Platinum(II) Complex via Downregulation of PI3K/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Topics: Animals; Apoptosis; Autophagy; Berberine; Cell Line, Tumor; Cell Proliferation; China; Female; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-akt; Signal Transduction; Thyroid Gland; Thyroid Neoplasms; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |